Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer

NCT00838578 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

65

Enrollment

INDUSTRY

Sponsor class

Stopped Per protocol, the study was terminated based on interim analysis results

Conditions

Colorectal Cancer

Interventions

BIOLOGICAL: KRN330
DRUG: Irinotecan

Sponsor

Kyowa Kirin Co., Ltd.

Collaborators

[object Object]